Insider Transactions in Q2 2021 at Dexcom Inc (DXCM)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.67%
|
$215,500
$431.49 P/Share
|
|
Jun 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.69%
|
$459,654
$426.37 P/Share
|
|
Jun 22
2021
|
Jay S Skyler Director |
SELL
Open market or private sale
|
Indirect |
20,000
-25.47%
|
$8,520,000
$426.38 P/Share
|
|
Jun 11
2021
|
Sumi Shrishrimal SVP Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
400
-2.99%
|
$160,400
$401.09 P/Share
|
|
Jun 09
2021
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
22,755
-21.59%
|
$8,988,225
$395.0 P/Share
|
|
Jun 03
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Open market or private sale
|
Indirect |
2,391
-12.74%
|
$896,625
$375.0 P/Share
|
|
Jun 03
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
BUY
Other acquisition or disposition
|
Indirect |
18,774
+50.0%
|
-
|
|
Jun 03
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Other acquisition or disposition
|
Direct |
18,774
-53.17%
|
-
|
|
Jun 03
2021
|
Nicholas Augustinos Director |
SELL
Open market or private sale
|
Direct |
806
-20.58%
|
$294,996
$366.99 P/Share
|
|
May 28
2021
|
Quentin S. Blackford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,223
-15.99%
|
$2,708,625
$375.0 P/Share
|
|
May 26
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.6%
|
$175,000
$350.0 P/Share
|
|
May 25
2021
|
Sumi Shrishrimal SVP Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
1,461
-9.84%
|
$517,194
$354.79 P/Share
|
|
May 24
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.29%
|
$374,413
$347.75 P/Share
|
|
May 24
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
600
-3.97%
|
$207,600
$346.74 P/Share
|
|
May 21
2021
|
Steven R Altman Director |
BUY
Grant, award, or other acquisition
|
Direct |
910
+50.0%
|
-
|
|
May 21
2021
|
Nicholas Augustinos Director |
BUY
Grant, award, or other acquisition
|
Direct |
918
+18.99%
|
-
|
|
May 21
2021
|
Richard Alexander Collins Director |
BUY
Grant, award, or other acquisition
|
Direct |
910
+50.0%
|
-
|
|
May 21
2021
|
Karen M Dahut Director |
BUY
Grant, award, or other acquisition
|
Direct |
918
+30.64%
|
-
|
|
May 21
2021
|
Mark G Foletta Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,054
+50.0%
|
-
|
|
May 21
2021
|
Bridgette P Heller Director |
BUY
Grant, award, or other acquisition
|
Direct |
919
+17.39%
|
-
|
|
May 21
2021
|
Barbara Kahn Director |
BUY
Grant, award, or other acquisition
|
Direct |
918
+50.0%
|
-
|
|
May 21
2021
|
Kyle Malady Director |
BUY
Grant, award, or other acquisition
|
Direct |
910
+29.43%
|
-
|
|
May 21
2021
|
Jay S Skyler Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+50.0%
|
-
|
|
May 21
2021
|
Eric Topol Director |
BUY
Grant, award, or other acquisition
|
Direct |
919
+50.0%
|
-
|
|
May 20
2021
|
Steven R Altman Director |
BUY
Other acquisition or disposition
|
Indirect |
806
+5.52%
|
-
|
|
May 20
2021
|
Steven R Altman Director |
SELL
Other acquisition or disposition
|
Direct |
806
-100.0%
|
-
|
|
May 20
2021
|
Richard Alexander Collins Director |
BUY
Other acquisition or disposition
|
Indirect |
787
+8.29%
|
-
|
|
May 20
2021
|
Richard Alexander Collins Director |
SELL
Other acquisition or disposition
|
Direct |
787
-100.0%
|
-
|
|
May 20
2021
|
Mark G Foletta Director |
BUY
Other acquisition or disposition
|
Indirect |
895
+5.97%
|
-
|
|
May 20
2021
|
Mark G Foletta Director |
SELL
Other acquisition or disposition
|
Direct |
895
-100.0%
|
-
|
|
May 20
2021
|
Barbara Kahn Director |
BUY
Other acquisition or disposition
|
Indirect |
787
+9.31%
|
-
|
|
May 20
2021
|
Barbara Kahn Director |
SELL
Other acquisition or disposition
|
Direct |
787
-100.0%
|
-
|
|
May 20
2021
|
Jay S Skyler Director |
BUY
Other acquisition or disposition
|
Indirect |
822
+2.36%
|
-
|
|
May 20
2021
|
Jay S Skyler Director |
SELL
Other acquisition or disposition
|
Direct |
822
-100.0%
|
-
|
|
May 20
2021
|
Eric Topol Director |
BUY
Other acquisition or disposition
|
Indirect |
833
+0.9%
|
-
|
|
May 20
2021
|
Eric Topol Director |
SELL
Other acquisition or disposition
|
Direct |
833
-100.0%
|
-
|
|
May 03
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
5,535
-0.72%
|
$2,103,300
$380.53 P/Share
|
|
Apr 26
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.53%
|
$207,500
$415.83 P/Share
|
|
Apr 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.66%
|
$442,390
$410.2 P/Share
|
|
Apr 15
2021
|
Paul R Flynn EVP Global Revenue |
SELL
Open market or private sale
|
Direct |
758
-5.8%
|
$303,200
$400.0 P/Share
|
|
Apr 05
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
6,221
-1.79%
|
$2,276,886
$366.64 P/Share
|